Cargando…

Using a Mathematical Modeling To Simulate Pharmacokinetics and Urinary Glucose Excretion of Luseogliflozin and Explore the Role of SGLT1/2 in Renal Glucose Reabsorption

[Image: see text] (1) Purpose: To develop a mathematical model combining physiologically based pharmacokinetic and urinary glucose excretion (PBPK-UGE) to simultaneously predict pharmacokinetic (PK) and UGE changes of luseogliflozin (LUS) as well as to explore the role of sodium-glucose cotransporte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhongjian, Wang, Guopeng, Ren, Jiawei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9798748/ https://www.ncbi.nlm.nih.gov/pubmed/36591124 http://dx.doi.org/10.1021/acsomega.2c06483

Ejemplares similares

LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2
por: Powell, David R, et al.
Publicado: (2015)

Mouse Models with SGLT2 Mutations: Toward Understanding the Role of SGLT2 beyond Glucose Reabsorption
por: Unno, Keiko, et al.
Publicado: (2023)

Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans
por: Lu, Yasong, et al.
Publicado: (2014)

Luseogliflozin, a SGLT2 Inhibitor, Does Not Affect Glucose Uptake Kinetics in Renal Proximal Tubules of Live Mice
por: Zhang, Anqi, et al.
Publicado: (2021)

Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?
por: Liu, Jiwen (Jim), et al.
Publicado: (2012)

Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus
por: Jinnouchi, Hideaki, et al.
Publicado: (2016)

SGLT2i: beyond the glucose-lowering effect
por: Ni, Lihua, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment
por: Samukawa, Yoshishige, et al.
Publicado: (2018)

Renal threshold for glucose reabsorption predicts diabetes improvement by sodium‐glucose cotransporter 2 inhibitor therapy
por: Osaki, Aya, et al.
Publicado: (2016)

OR26-01 Epinephrine Is Essential for Normal Renal Glucose Reabsorption via the Glucose Transporter GLUT2
por: Elsheikh, Arwa Mahmoud, et al.
Publicado: (2020)

Renal polyamine excretion, tubular amino acid reabsorption and molecular genetics in cystinuria
por: Langen, H., et al.
Publicado: (2000)

Lower Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 Inhibitors to the Improvement of Plasma Glucose Control Compared with T2DM
por: Osaki, Aya, et al.
Publicado: (2019)

Thyroid hormone treatment decreases hepatic glucose production and renal reabsorption of glucose in alloxan‐induced diabetic Wistar rats
por: Teixeira, Silvania da Silva, et al.
Publicado: (2016)

Luseogliflozin Additively Enhances the Glucose-Lowering Effect of an Incretin Modulator in a High-Carbohydrate Diet
por: Lee, Gendai
Publicado: (2022)

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
por: Qiang, Shirong, et al.
Publicado: (2015)

Urinary reabsorption in the rat kidney by anticholinergics
por: Oe, Hideki, et al.
Publicado: (2021)

Enteric reabsorption processes and their impact on drug pharmacokinetics
por: Ibarra, Manuel, et al.
Publicado: (2021)

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance
por: Scotcher, Daniel, et al.
Publicado: (2016)

Clinical and genetic determinants of urinary glucose excretion in patients with diabetes mellitus
por: Monobe, Keisuke, et al.
Publicado: (2020)

MON-639 Melanocortin 4 Receptor Contributes to Glucose Homeostasis by Regulating Kidney Glucose Reabsorption via the Glucose Transporter GLUT2
por: de Souza Cordeiro, Leticia M, et al.
Publicado: (2020)

Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus
por: Geist, Barbara Katharina, et al.
Publicado: (2023)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

Sodium‐glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low‐carbohydrate diet
por: Nishimura, R., et al.
Publicado: (2016)

Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
por: Ghezzi, Chiara, et al.
Publicado: (2018)

Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice
por: Bamba, Ryo, et al.
Publicado: (2021)

Morning Spot Urine Glucose-to-Creatinine Ratios Predict Overnight Urinary Glucose Excretion in Patients With Type 2 Diabetes
por: Kim, So Ra, et al.
Publicado: (2017)

A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor
por: Hwang, You-Cheol, et al.
Publicado: (2019)

Insulin enhances renal glucose excretion: relation to insulin sensitivity and sodium-glucose cotransport
por: Ferrannini, Ele, et al.
Publicado: (2020)

The Urinary Glucose Excretion by Sodium–Glucose Cotransporter 2 Inhibitor in Patients With Different Levels of Renal Function: A Systematic Review and Meta-Analysis
por: Hu, Suiyuan, et al.
Publicado: (2022)

Luseogliflozin inhibits high glucose-induced TGF-β2 expression in mouse cardiomyocytes by suppressing NHE-1 activity
por: Osaka, Naoya, et al.
Publicado: (2022)

Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study
por: Furukawa, Shinya, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium–glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus
por: Saito, Masako, et al.
Publicado: (2019)

Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages
por: Takahashi, Kiyohiko, et al.
Publicado: (2018)

Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study
por: Polidori, David, et al.
Publicado: (2013)

Prompt apoptotic response to high glucose in SGLT-expressing renal cells
por: Nilsson, Linnéa M., et al.
Publicado: (2019)

Osmotic diuresis by SGLT2 inhibition stimulates vasopressin‐induced water reabsorption to maintain body fluid volume
por: Masuda, Takahiro, et al.
Publicado: (2020)

High urinary excretion rate of glucose attenuates serum uric acid level in type 2 diabetes with normal renal function
por: Qin, Y., et al.
Publicado: (2021)

Na(+)-d-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion
por: Gorboulev, Valentin, et al.
Publicado: (2012)

Osmotic Water Transport with Glucose in GLUT2 and SGLT
por: Naftalin, Richard J.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_erm1s4ltsisidtcqhb0ck8n8oo